Unidad de Investigación Clínica de Cáncer Pulmón H12O-CNIO

Inicio | Investigación e innovación | Programas Científicos | Programa de Investigación Clínica | Unidad de Investigación Clínica de Cáncer Pulmón H12O-CNIO

Luis Gonzaga Paz-Ares
Luis Gonzaga Paz-Ares Jefe de Unidad de Investigación Clínica
T +34 (+34) 917 328 000 (Ext )


  • María Teresa Agullo
  • Irene Ferrer
  • Itziar Otano
  • Beatriz Soldevilla

Investigador Clínico I

  • Rocio García
  • José Luis Solórzano
  • Álvaro Conrado Ucero
  • Jon Zugazagoitia

Becarios Post-doctorales

  • María Magdalena Abraham
  • María Cristina Cirauqui
  • Juan Manuel Coya
  • Arantza Lamas
  • Miguel Ruiz
  • Gorka Ruiz de Garibay

Becarios Pre-Doctorales

  • Carlos Carretero
  • María Inés Díaz
  • María del Carmen Fernández-Luna
  • Santiago García
  • David Gómez
  • María Gutiérrez
  • Iván Hernández
  • Ángel Núñez
  • Beatriz Rubio
  • Joan Salvador Russo
  • Alba Santos Ramos
  • Patricia Yagüe

Técnicos de Laboratorio

  • Vera Adradas
  • Eva Álvarez
  • David Cáceres
  • Nuria Carrizo
  • Eva María Casas
  • Patricia Cozar
  • Laura García
  • Beatriz Gil
  • José María Gracia
  • Marta Jiménez
  • Patricia Llamas
  • Patricia Plaza
  • Laura Ramírez
  • Belén Revuelta
  • Rocío Suárez
  • César Vélez

Lung cancer continues to be the most frequent cause of cancer-related deaths worldwide. Our Unit focuses on the study of lung cancer, from fundamental research proposals to other more clinically oriented, always aiming to solve the problems of lung cancer patients. We are particularly interested in 2 research areas: the identification of new molecular biomarkers for diagnostic, prognostic, and predictive purposes; and the development of novel treatment strategies, including targeted therapies and immunotherapeutics. For example, we have contributed to elucidating the molecular determinants of EGFR or FGFR oncogenicity and have discovered biomarkers that may guide the efficacy of inhibitors of those receptors in lung cancer. We have continued to develop an extensive platform of patient-derived xenografts (PDXs) and organoids (PDOs) of non-small-cell and small cell lung cancers to test new therapeutic strategies. Finally, our Unit has extensive experience in taking new drugs to the clinic, as well as in conducting practice-changing phase II/III trials in the fields of personalised cancer care and immuno-oncology.